Source disclosure: February 06, 2026
Tsubota Laboratory Incorporated [4890.T]
TOKYO, Feb 06 (Pulse News Wire) – Tsubota Laboratory Incorporated (4890.T) announced positive preliminary results from its domestic clinical trial of the violet light irradiation device “TLG-001” aimed at myopia prevention. The study showed statistical significance in slowing myopia progression among children with shorter outdoor activity times.
No serious adverse events were reported, indicating the device's safety profile for continuous use in pediatric settings. Key findings included consistent trends in myopia suppression compared to previous data and maintained choroidal thickness.
In exploratory analyses focusing on subjects with less outdoor exposure, TLG-001 demonstrated statistically significant reductions in axial eye length and improved refractive outcomes under cycloplegia. Based on these insights, the company plans to refine patient selection criteria and evaluation methods for future trials, aiming to establish TLG-001 as a viable treatment option for myopia control.
Approximately 70% of Japanese elementary and middle school students could potentially benefit from targeted interventions based on their limited outdoor activities.
AI-translated content. 🟢 Confidence: High See terms • Original filing